Revisiting choline alphoscerate profile: A new, perspective, role in dementia?

International Journal of Neuroscience

Volumn 123, Issue 7, 2013, Pages 444-449

  Scapicchio, Pier Luigi ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Choline; Cognition; Dementia

Indexed keywords

ANIRACETAM; BENZODIAZEPINE; CHOLINE ALFOSCERATE; DONEPEZIL; GALANTAMINE; GLUTAMIC ACID; IDEBENONE; MEMANTINE; PHOSPHATIDYLINOSITOL 3 KINASE; PIRACETAM; PLACEBO; PROTEIN BCL 2; RIVASTIGMINE; SCOPOLAMINE;

ALZHEIMER DISEASE; AMNESIA; ARTICLE; BEHAVIOR DISORDER; BRAIN INFARCTION; BRAIN INJURY; CEREBROVASCULAR ACCIDENT; CHOLINERGIC TRANSMISSION; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE DEFECT; DEMENTIA; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HUMAN RELATION; HYPERTENSION; LEARNING DISORDER; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PASSIVE AVOIDANCE; PILOT STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPONTANEOUSLY HYPERTENSIVE RAT; TRANSIENT ISCHEMIC ATTACK;

ANIMALS; COGNITION DISORDERS; DEMENTIA; GLYCERYLPHOSPHORYLCHOLINE; HUMANS; NOOTROPIC AGENTS;

EID: 84879163754     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2013.765870     Document Type: Article

References (41)

1. Burns A, Iliffe S. Dementia. BMJ 2009 Feb;338:405-9.
2. Lobo A, Launer LJ, Fratiglioni L, et al. Neurologic diseases in the elderly research group. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurology 2000;54(Suppl 5):S4-S9.
3. Brayne C. The elephant in the room - healthy brains in later life, epidemiology and public health. Nat Rev Neurosci 2007 Mar;8:233-9.
4. Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982 Jul;217:408-14
5. Bartus RT. On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000 Jun;163(2):495-529
6. Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: A systematic review and meta-Analysis. Clin Interv Aging 2008;3:211-25
7. Sigala S, Imperato A, Rizzonelli P, et al. L-Aglycerylphosphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat. Eur J Pharmacol 1992 Feb;211:351-8.
8. Pinardi G, Pelissier T, Kramer V, et al. Effects of CDPcholine on acetylcholine-induced relaxation of the perfused carotid vascular beds of the rat. Gen Pharmacol 1994 Jul; 25: 635-8.
9. Dixon CE, Ma X, Marion DW. Effects of CDP-choline treatment on neurobehavioral deficits after TBI and on hippocampal and neocortical acetylcholine release. J Neurotrauma 1997 Mar;14:161-9.
10. Parnetti L, Mignini F, Tomassoni D, et al. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: Ineffective approaches or need for re-evaluation? J Neurol Sci 2007;257:264-9.
11. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebocontrolled preservation of function survival study of donepezil in AD patients. Neurology 2001 Aug;57:481-8.
12. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001 Aug;57:489-95
13. Kidd PM. Alzheimer's disease, amnestic mild cognitive impairment, and age-Associated memory impairment: Current understanding and progress toward integrative prevention. Altern Med Rev 2008 Jun;13:85-115
14. Abbiati G, Fossati T, Lachmann G, et al. Absorption, tissue distribution and excretion of radiolabelled compounds in rats after administration of [14C]-L-A-glycerylphosphorylcholine. Eur J Drug Metab Pharmacokinet 1993 Apr-Jun;18:173-80
15. Trabucchi M, Govoni S, Battaini F. Changes in the interaction between CNS cholinergic and dopaminergic neurons induced by L-A-glycerylphosphorylcholine, a cholinomimetic drug. Farmaco Sci 1986 Apr;41:325-34
16. Lopez CM, Govoni S, Battaini F, et al. Effect of a new cognitive enhancer, alpha-glycerylphosporylcholine, on scopalamineinduced amnesia and brain acetylcholine. Pharmacol Biochem Behav 1991 Aug;39:35-40
17. Amenta F, Parnetti L, Gallai V, Wallin A. Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches? Mech Ageing Dev 2001 Nov;122:2025-40
18. Amenta F, Tayebati SK, Vitali D, Di Tullio MA. Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: An approach for enhancing cholinergic neurotransmission.Mech Ageing Dev 2006 Feb;127:173-9.
19. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline. Ann Intern Med 2008 Mar;148:379-97
20. Tayebati SK, Di Tullio MA, Tomassoni D, Amenta F. Neuroprotective effect of treatment with galantamine and choline alphoscerate on brain microanatomy in spontaneously hypertensive rats J Neurol Sci 2009 Aug;283:187-94
21. Tomassoni D, Avola R, Mignini F, et al. Effect of treatment with choline alphoscerate on hippocampus microanatomy and glial reaction in spontaneously hypertensive rats. Brain Res 2006 Nov;1120(1):183-90
22. Aleppo G, Nicoletti F, Sortino MA, et al. Chronic L-Alphaglyceryl- phosphoryl-choline increases inositol phosphate formation in brain slices and neuronal cultures. Pharmacol Toxicol 1994 Feb;74:95-100
23. Akaike A. Preclinical evidence of neuroprotection by cholinesterase inhibitors. Alzheimer Dis Assoc Disord 2006 Apr-Jun;20(2 Suppl 1):S8-11
24. Gallelli L. Choline alphoscerate pharmacology and its role in the treatment of cognitive impairment related to neurological disorders. Funct Neurol 2011;Suppl: 1-7.
25. Canal N, Franceschi M, Alberoni M, et al. Effect of L- Alphaglycerylphosphorylcholine on amnesia caused by scopolamine. Int J Clin Pharm Ther Tox 1991 Mar;29(3):103-7.
26. Canal N, Alberoni M, Bressi S, et al. Confronto degli effetti di un pretrattamento con colina alfoscerato, idebenone, aniracetam e placebo sull'amnesia indotta da scopolamina. Basi Raz Ter 1990;20:102-7.
27. Ceda GP, Ceresini L, Denti G, et al. Alphaglycerylphosphorylcholine administration increases the GH responses to GHRH of young and elderly subjects. Horm Metab Res 1992 Mar;24(3):119-21
28. Parnetti L, Amenta F, Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: An analysis of published clinical data. Mech Ageing Dev 2001 Nov;122(16):2041-55
29. De JesusMorenoMorenoM. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: A multicenter, doubleblind, randomized, placebo-controlled trial. Clin Ther 2003 Jan;25(1):178-93
30. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia : A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011 Sep;42(9):2672-713
31. Barbagallo Sangiorgi G, Barbagallo M. Giordano M, et al. Alpha-glycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial. Ann NY Acad Sci 1994 Jun 30;717:253-69
32. Cummings JL. Cholinesterase inhibitors for treatment of dementia associated with Parkinson's disease. J Neurol Neurosurg Psychiat 2005 Jul;76(7):903-4.
33. Winblad B, Jones RW, Wirth Y, et al. Memantine in moderate to severe Alzheimer's disease: A meta-Analysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007;24(1): 20-7.
34. Levin OS, Batukaeva LA, Anikina MA, Yunishchenko NA. Efficacy and safety of choline alphoscerate (cereton) in patients with Parkinson's disease with cognitive impairments. Neurosci Behav Physiol 2011;41:47-51
35. Jones RW. Have cholinergic therapies reached their clinical boundary in Alzheimer's disease? Int J Geriatr Psychiatry 2003 Sep;18(Suppl 1):S7-13
36. Brownawell AM, Carmines EL, Federica Montesano F. Safety assessment of AGPC as a food ingredient Food Chem Toxicol 2011 Jun;49(6):1303-15
37. Craig LA, Hong NS, McDonald RJ. Revisiting the cholinergic hypothesis in the development of Alzheimer's disease. Neurosci Biobehav Rev 2011 May;35(6):1397-409
38. Doody RS, Dunn JK, Clark CM, et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord 2001 Jul-Aug;12(4):295-300
39. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDPcholine) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev 2005;2:CD000269
40. Amenta F, Tayebati SK, Vitali D, Di Tullio MA. Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: An approach for enhancing cholinergic neurotransmission. Mech Ageing Dev 2006 Feb;127(2):173-9.
41. Amenta F, Tayebati SK. Pathways of acetylcholine synthesis, transport and release as targets for treatment of adult-onset cognitive dysfunction. Curr Med Chem 2008;15(5):488-98